COVID-19 Monoclonal Antibodies Scale back Hospital Keep And Danger Of Loss of life By 60%: Examine
New York, May 18: Administration of monoclonal antibodies – a Covid-19 treatment given early after a coronavirus infection – can reduce the risk of hospitalizations and deaths for people most likely to have complications from the disease by 60 percent, according to the study.
Monoclonal antibodies are a type of drug that detects the Covid-19 virus in a person’s body and prevents it from infecting their cells and replicating.
The study, conducted by researchers at the University of Pittsburgh, found that people 65 and over who received bamlanivimab – a monoclonal antibody – were almost three times less likely to be hospitalized or died in the following month compared to their untreated counterparts. COVID-19 can infect cells in the eye, US researchers say.
The results were less pronounced in younger populations, but overall more positive results were seen in those who received monoclonal antibody infusions than those who did not. The results will be published in the journal Open Forum Infectious Diseases.
“The fact that we have found that bamlanivimab is so effective in keeping our patients with Covid-19 out of hospital bodes well for the future use of the currently available monoclonal therapies that we are currently investigating,” said the lead author Ryan Bariola. Associate Professor in Pitt’s Infectious Disease Department.
“When given early to high-risk patients, this treatment will prevent complications related to Covid-19,” Bariola added.
The team analyzed data from 232 patients treated with bamlanivimab to see how they had fared since their infusions. They compared data from antibody-treated patients with that of a matching group of patients of similar age and health who had contracted Covid-19 who were eligible for treatment but were not receiving it. Pfizer COVID-19 vaccine for people who received first dose of AstraZeneca vaccine safely and effectively, finds Spanish study.
The data also showed a greater positive effect when the previous patients received treatment after contracting the virus and a very low rate of side effects from the infusion, all of which were mild.
“If we see one important finding in our data it is this: If you are receiving Covid-19 and are at higher risk of developing serious illnesses, ask your doctor about monoclonal antibodies.” Do not hesitate. Early treatment while your symptoms are still mild may be imperative, “said Graham Snyder, associate professor at Pitt’s School of Medicine.
(The above story first appeared on May 19, 2021 at 1:33 p.m. IST. For more politics, world, sport, entertainment and lifestyle news and updates, visit our website at latestly.com.)